The nonexclusive deal includes Personal Genome Diagnostics' US Food and Drug Administration-cleared Elio Tissue Complete cancer genomic profiling assay.
The group envisions using PGDx's technology to identify effective therapy options for cancer patients and improve monitoring of patient response to therapy.
The group will create a kitted next-generation sequencing tool that will help researchers and biopharma firms conduct biomarker discovery work on patient blood samples.
A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.
The in vitro diagnostic uses next-generation sequencing to detect clinically actionable genetic variants to guide therapy selection for cancer patients.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
